Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biohaven Pharmaceutical Holding Co. Ltd.
Headquarters: New Haven, CT, United States of America
Website: N/A
Year Founded: 2014
Status: Acquired
BioCentury | Jan 13, 2025
Deals
Lilly catches Relay in PI3Ka race via Scorpion acquisition
A spinout will house precision oncology assets from Scorpion
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Oct 25, 2024
Deals
James Sabry on industry-shaping changes in innovation and deal-making
Business development veteran talks to BioCentury as he transitions from Roche to BioMarin, entering the one biotech segment he’s not yet been in
BioCentury | Jan 23, 2024
Deals
Sanofi gets clinical AAT therapy via takeout-and-spinout deal with Inhibrx
Echoing Biohaven’s arrangement with Pfizer, most Inhibrx assets will land in a well-capitalized newco
BioCentury | Sep 19, 2023
Emerging Company Profile
Magnet: taking molecular glues beyond protein degradation with $50M
The company discovers small molecules that induce desired protein-protein interactions using an arsenal of screening technologies
BioCentury | Aug 29, 2023
Finance
Where is the sweet spot for M&A?
Back to School 2023: An analysis of biotech takeouts by market cap size
BioCentury | Aug 18, 2023
Management Tracks
CSL names first chief sustainability officer
Plus: Jones hired as CCO at NewAmsterdam, and updates from Foresight, Kronos, Antheia and more
BioCentury | Aug 17, 2023
Data Byte
Oral CGRP therapies top migraine market, as all boats rose in 2Q23
All seven CGRP inhibitors on the market had sales growth last quarter, with oral therapies from Pfizer and AbbVie the top performers
BioCentury | Jun 24, 2023
Management Tracks
Graphite’s Young to join Bicycle
Plus: Integra hires Knight and updates from Apogee
BioCentury | Mar 13, 2023
Deals
Pfizer believes $43B Seagen deal positions it to fulfill most of 2030 revenue goal
Provided regulators clear deal, pharma sees $10B+ in added revenue from ADC company by early next decade
Items per page:
1 - 10 of 103